glyburide has been researched along with Weight Gain in 18 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, A1C, and weight gain." | 9.14 | Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). ( Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Yu, D; Zinman, B, 2010) |
| "Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, A1C, and weight gain." | 5.14 | Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). ( Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Yu, D; Zinman, B, 2010) |
| "Combination therapy with bedtime insulin plus metformin prevents weight gain." | 5.09 | Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. ( Heikkilä, M; Nikkilä, K; Ryysy, L; Tulokas, T; Vanamo, R; Yki-Järvinen, H, 1999) |
| "4%) had at least one episode of hypoglycemia, most often in the setting of glyburide." | 4.12 | Antenatal maternal hypoglycemia in women with gestational diabetes mellitus and neonatal outcomes. ( Cruz, M; Davitt, C; Harrison, RK; Palatnik, A; Saravanan, V, 2022) |
| "To evaluate treatment effectiveness (diet alone, insulin or glyburide) on maternal weight gain in gestational diabetes (GDM)." | 3.83 | Weight gain in gestational diabetes: the effect of treatment modality. ( Bimson, B; Brustman, LE; El Daouk, M; Langer, O; Scarpelli, S, 2016) |
| "No weight gain was observed in patients treated with nateglinide." | 2.72 | Nateglinide with glibenclamide examination using the respiratory quotient (RQ). ( Harada, S; Ito, S; Nakaya, Y; Nomura, M, 2006) |
| "Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0." | 2.72 | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. ( Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| " Fasting and mean 7- and 8-point blood glucose profiles, blood lipid levels, plasminogen activator inhibitor levels, adverse events, and hypoglycemia frequency were also compared." | 2.71 | Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. ( Chow, CC; Filipczak, R; Joshi, P; Lertoft, B; Rastam, J; Raz, I; Shaban, J; Stranks, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Harrison, RK | 1 |
| Saravanan, V | 1 |
| Davitt, C | 1 |
| Cruz, M | 1 |
| Palatnik, A | 1 |
| Feghali, M | 1 |
| Atlass, J | 1 |
| Abebe, KZ | 1 |
| Comer, D | 1 |
| Catov, J | 1 |
| Caritis, S | 1 |
| Arslanian, S | 1 |
| Scifres, C | 1 |
| Lamos, EL | 1 |
| Stein, SA | 1 |
| Davis, SN | 1 |
| Brustman, LE | 1 |
| Langer, O | 1 |
| Bimson, B | 1 |
| Scarpelli, S | 1 |
| El Daouk, M | 1 |
| Kahn, SE | 2 |
| Haffner, SM | 2 |
| Viberti, G | 2 |
| Herman, WH | 2 |
| Lachin, JM | 2 |
| Kravitz, BG | 2 |
| Yu, D | 1 |
| Paul, G | 1 |
| Holman, RR | 2 |
| Zinman, B | 2 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Reyes-Morales, H | 1 |
| Mino-León, D | 1 |
| Doubova, SV | 1 |
| Flores-Hernández, S | 1 |
| Silva, JC | 1 |
| Fachin, DR | 1 |
| Coral, ML | 1 |
| Bertini, AM | 1 |
| Nesto, RW | 1 |
| Bell, D | 1 |
| Bonow, RO | 1 |
| Fonseca, V | 1 |
| Grundy, SM | 1 |
| Horton, ES | 1 |
| Le Winter, M | 1 |
| Porte, D | 1 |
| Semenkovich, CF | 1 |
| Smith, S | 1 |
| Young, LH | 1 |
| Kahn, R | 1 |
| Raz, I | 1 |
| Stranks, S | 1 |
| Filipczak, R | 1 |
| Joshi, P | 1 |
| Lertoft, B | 1 |
| Rastam, J | 1 |
| Chow, CC | 1 |
| Shaban, J | 1 |
| Schreiber, SA | 1 |
| Russmann, A | 1 |
| Harada, S | 1 |
| Nomura, M | 1 |
| Nakaya, Y | 1 |
| Ito, S | 1 |
| Heise, MA | 1 |
| Jones, NP | 1 |
| O'Neill, MC | 1 |
| Nathan, DM | 1 |
| Bugdayci, G | 1 |
| Altan, N | 1 |
| Sancak, B | 1 |
| Bukan, N | 1 |
| Kosova, F | 1 |
| Kamgang, R | 1 |
| Mboumi, RY | 1 |
| Fondjo, AF | 1 |
| Tagne, MA | 1 |
| N'dillé, GP | 1 |
| Yonkeu, JN | 1 |
| Guiot, Y | 1 |
| Henquin, JC | 1 |
| Rahier, J | 1 |
| Yki-Järvinen, H | 1 |
| Ryysy, L | 1 |
| Nikkilä, K | 1 |
| Tulokas, T | 1 |
| Vanamo, R | 1 |
| Heikkilä, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.[NCT01998113] | 2,509 participants (Actual) | Observational | 2013-03-31 | Completed | |||
| The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study.[NCT00285805] | 13 participants (Actual) | Interventional | 2006-02-28 | Completed | |||
| Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359] | 138 participants (Anticipated) | Observational [Patient Registry] | 2019-05-06 | Recruiting | |||
| Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus[NCT02639988] | 1,000 participants (Anticipated) | Observational | 2016-04-13 | Suspended | |||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin[NCT02026310] | 40 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
2 reviews available for glyburide and Weight Gain
| Article | Year |
|---|---|
Sulfonylureas and meglitinides: historical and contemporary issues.
Topics: Animals; Benzamides; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glyburide; History, 20th | 2013 |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Topics: Blood Volume; Clinical Trials as Topic; Comorbidity; Contraindications; Diabetes Mellitus, Type 2; D | 2003 |
6 trials available for glyburide and Weight Gain
| Article | Year |
|---|---|
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Topics: Adult; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic | 2010 |
Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Glucose Tolerance Test; Glyburide | 2012 |
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hem | 2005 |
Nateglinide with glibenclamide examination using the respiratory quotient (RQ).
Topics: Aged; Blood Glucose; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glyburide; Humans | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
Topics: Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Drug Administratio | 1999 |
10 other studies available for glyburide and Weight Gain
| Article | Year |
|---|---|
Antenatal maternal hypoglycemia in women with gestational diabetes mellitus and neonatal outcomes.
Topics: Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agent | 2022 |
Treatment of Gestational Diabetes Mellitus and Offspring Early Childhood Growth.
Topics: Adult; Birth Weight; Child Development; Child, Preschool; Cohort Studies; Diabetes, Gestational; Die | 2021 |
Weight gain in gestational diabetes: the effect of treatment modality.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Diet Therapy; Female; Glyburide; Humans; Insulin; Pregn | 2016 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Foll | 2012 |
Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glybu | 2006 |
Thiazolidinediones for initial treatment of type 2 diabetes?
Topics: Algorithms; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitaz | 2006 |
The effect of the sulfonylurea glyburide on glutathione-S-transferase and glucose-6-phosphate dehydrogenase in streptozotocin-induced diabetic rat liver.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucosephosphate Dehydrogenase; Glutathione | 2006 |
Antihyperglycaemic potential of the water-ethanol extract of Kalanchoe crenata (Crassulaceae).
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2008 |
Effects of glibenclamide on pancreatic beta-cell proliferation in vivo.
Topics: Aging; Animals; Bromodeoxyuridine; Cell Division; Cell Nucleus; Cell Size; Female; Glyburide; Immuno | 1994 |